Pharma Pricing and Market Access 2019 Day 2

09:20

Sponsor presentation

Panel discussion
10:20

Morning Refreshments

PRICING & MARKET ACCESS

RARE DISEASES

AFFORDABILITY

ADVANCED THERAPIES

MANAGED ENTRY AGREEMENTS

EVIDENCE

AFFORDABILITY
11:05

Pharmaceutical Affordability

  • Ability to Pay versus Willingness to Pay
  • Considerations for Product-specific and Patient-specific affordability programs
  • Partnering with payers/policy makers
EVIDENCE
11:05

Federated & Harmonised Real World Research in the EU 2020+: A Convergence of Intent, Collaboration & Technology?

  • The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
  • Data harmonisation – an international initiative and the Rosetta Stone of RWD?
  • What have we learned from IMI EMIF, from its original inception, project experience, and sustainability scale up
  • The premise for EHDN, aims and likely impact
  • Meeting the needs of multiple stakeholders
PRICING AND MARKET ACCESS
11:25

EUnetHTA and Joint Assessments: Focus on the BeNeLuxA Collaboration

Rosemary Jose, Associate Director of Strategic Market Access, Pharmerit International
RARE DISEASES
11:25

Sponsor presentation

ADVANCED THERAPIES
11:25

Sponsor presentation

MANAGED ENTRY AGREEMENTS
11:25

Sponsor presentation

EVIDENCE
11:25

Sponsor presentation

ADVANCED THERAPIES
11:45

Examining the regulatory landscape for CAR-T

  • CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
  • Drug or therapeutic method: first experiences in the German health care system
  • Most expensive cancer treatment ever: New approaches for affordability and sustainability

PRICING & MARKET ACCESS

RARE DISEASES

CONTRACTING AND PRICE TENDERING

ADVANCED THERAPIES

PATIENT AND PAYER ENGAGEMENT

RARE DISEASES
14:05

Chair’s remarks

CONTRACTING AND PRICE TENDERING
14:05

Chair’s remarks

ADVANCED THERAPIES
14:05

Chair’s remarks

PATIENT AND PAYER ENGAGEMENT
14:05

Chairs Opening Remarks

EVIDENCE
14:05

Chair’s remarks

CONTRACTING AND PRICE TENDERING
14:10

Biosimilars and their impact on drug contracting in the value chain

Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
EVIDENCE
14:10

Precision medicine in oncology: challenges and possible solutions from a payer’s perspective

  • What are the key challenges we face in commissioning tests and treatments in this fast-paced and innovative field?
  • How can we ensure our patients have access to tests and treatments that are safe and effective despite limited evidence?
  • What solutions could be considered to manage costs to payers (and our customers) and safeguard precision medicine as a sustainable option in the future?
PRICING AND MARKET ACCESS
14:30

Sponsor presentation

RARE DISEASES
14:30

Sponsor presentation

CONTRACTING AND PRICE TENDERING
14:30

Sponsor presentation

ADVANCED THERAPIES
14:30

Risks in CAR-T commercialisation - understanding barriers to entry

Akshay Kumar, Senior Director, Huron Consulting Group
Francois Lucas, Senior Director, Huron Consulting Group
PATIENT AND PAYER ENGAGEMENT
14:30

Sponsor presentation

EVIDENCE
14:30

Sponsor presentation

MEDCIAL AND GOVERNMENTAL AFFAIRS

RARE DISEASES
14:50

TBC

PRICING & MARKET ACCESS

RARE DISEASES

ADVANCED THERAPIES

MEDICAL DEVICES

EVIDENCE

PRICING AND MARKET ACCESS
15:40

Chair’s remarks

RARE DISEASES
15:40

Chair’s remarks

ADVANCED THERAPIES
15:40

Chair’s remarks

MEDICAL DEVICES
15:40

Chair’s remarks

Chair’s remarks

ADVANCED THERAPIES
15:45

Bringing gene therapies to market – strategic considerations

Darren Walsh, Senior Director - Market Access & Govt. Affairs – EU, Orchard Therapeutics
MEDICAL DEVICES
15:45

Presentation

PRICING AND MARKET ACCESS
16:05

Sponsor presentation

RARE DISEASES
16:05

Sponsor presentation

MEDICAL DEVICES
16:05

Sponsor presentation

EVIDENCE
16:05

Sponsor presentation

PRICING AND MARKET ACCESS
16:25

HTA in Switzerland

  • Legal Context of HTA in Switzerland
  • HTA Processes
  • Implementation of HTA
MEDICAL DEVICES
16:25

Presentation

PRICING AND MARKET ACCESS
16:45

Chair's closing remarks

ADVANCED THERAPIES
16:45

Chair's closing remarks

MEDICAL DEVICES
16:45

Chair's closing remarks

EVIDENCE
16:45

Chair's closing remarks

last published: 18/Jan/19 15:55 GMT